Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study

Rezultati

Naziv:	Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
Autori :	O'Shaughnessy, Joyce; ...; Cvetanovic, Ana; ...; Stamatovic, Ljiljana
Godina:	2020
Publikacija:	ANNALS OF ONCOLOGY
ISSN:	0923-7534 Annals of Oncology Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 31 str. S306-S307
DOI:	10.1016/j.annonc.2020.08.287
WoS-ID:	000573469100165
URI:	https://enauka.gov.rs/handle/123456789/796971
Projekat:	F. Hoffmann-La Roche Ltd.Hoffmann-La Roche
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

5
OpenCitations

10
WEB OF SCIENCE^TM

Alt metrika

Dimensions

Unpaywall

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.